APO Research
Talk to an analyst

APO RESEARCH · REPORT

Benign Prostatic Hyperplasia (BPH) Drugs

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Selected research

Industry Research

Benign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2026

29 December 2025125 pages

Choose your research edition.

Industry ResearchBenign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Benign Prostatic Hyperplasia (BPH) Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Report Scope

Read the full market overview

This report quantifies the global Benign Prostatic Hyperplasia (BPH) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Benign Prostatic Hyperplasia (BPH) Drugs Market by Company

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

Hospitals

Drugstores

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Benign Prostatic Hyperplasia (BPH) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Manufacturers (2021-2026) Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eli Lilly Company Information Table 19. Eli Lilly Business Overview Table 20. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 22. Eli Lilly Recent Developments Table 23. GlaxoSmithKline Company Information Table 24. GlaxoSmithKline Business Overview Table 25. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 27. GlaxoSmithKline Recent Developments Table 28. Astellas Pharma Company Information Table 29. Astellas Pharma Business Overview Table 30. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 32. Astellas Pharma Recent Developments Table 33. Sanofi Company Information Table 34. Sanofi Business Overview Table 35. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 37. Sanofi Recent Developments Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 42. Pfizer Recent Developments Table 43. Abbott Company Information Table 44. Abbott Business Overview Table 45. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 47. Abbott Recent Developments Table 48. Allergan Company Information Table 49. Allergan Business Overview Table 50. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 52. Allergan Recent Developments Table 53. TEVA Company Information Table 54. TEVA Business Overview Table 55. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 57. TEVA Recent Developments Table 58. Mylan Company Information Table 59. Mylan Business Overview Table 60. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 62. Mylan Recent Developments Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 67. Novartis Recent Developments Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 72. Merck Recent Developments Table 73. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 74. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021-2026) & (M Units) Table 75. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2026) Table 76. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2027-2032) & (M Units) Table 77. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2027-2032) Table 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 79. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2021-2026) Table 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2027-2032) Table 82. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 84. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 85. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 87. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 89. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 90. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 92. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 94. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 95. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 96. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 97. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 99. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 100. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 101. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 102. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 104. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 105. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 106. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 107. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 108. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 109. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2021-2026) Table 110. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2027-2032) Table 111. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 112. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 113. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2021-2026) Table 114. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2027-2032) Table 115. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2026) & (US$/Unit) Table 116. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2027-2032) & (US$/Unit) Table 117. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 118. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 119. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2021-2026) Table 120. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2027-2032) Table 121. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 122. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 123. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2021-2026) Table 124. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2027-2032) Table 125. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2026) & (US$/Unit) Table 126. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2027-2032) & (US$/Unit) Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List Table 130. Benign Prostatic Hyperplasia (BPH) Drugs Customers List Table 131. Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends Table 132. Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers Table 133. Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints Table 134. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Benign Prostatic Hyperplasia (BPH) Drugs Product Image Figure 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2021-2032) & (M Units) Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Alpha-Blocker Product Image Figure 10. Phosphodiesterase Type-5 Inhibitors Product Image Figure 11. Others Product Image Figure 12. Hospitals Product Image Figure 13. Drugstores Product Image Figure 14. Others Product Image Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region in 2025 Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region in 2025 Figure 22. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country in 2025 Figure 23. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2032) Figure 24. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2032) Figure 25. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country in 2025 Figure 29. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2032) Figure 30. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2032) Figure 31. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country in 2025 Figure 42. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2032) Figure 44. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country in 2025 Figure 53. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2032) Figure 54. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2032) Figure 55. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country in 2025 Figure 60. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2021-2032) Figure 62. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2021-2032) Figure 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2021-2032) Figure 69. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2021-2032) Figure 70. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2021-2032) Figure 71. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2021-2032) Figure 72. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2021-2032) Figure 73. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Figure 74. Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Alpha-Blocker
  • Phosphodiesterase Type-5 Inhibitors
  • Others
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Eli Lilly
  • GlaxoSmithKline
  • Astellas Pharma
  • Sanofi
  • Pfizer
  • Abbott
  • Allergan
  • TEVA
  • Mylan
  • Novartis
  • Merck

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2021-2032)
  4. 2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2021-2032)
  5. 2.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (2021-2032)
  6. 2.3 Benign Prostatic Hyperplasia (BPH) Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Alpha-Blocker
  9. 2.3.3 Phosphodiesterase Type-5 Inhibitors
  10. 2.3.4 Others
  11. 2.4 Benign Prostatic Hyperplasia (BPH) Drugs by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospitals
  14. 2.4.3 Drugstores
  15. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Manufacturers (2021-2026)
  3. 3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Established Date
  9. 3.9 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eli Lilly
  2. 4.1.1 Eli Lilly Company Information
  3. 4.1.2 Eli Lilly Business Overview
  4. 4.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  6. 4.1.5 Eli Lilly Recent Developments
  7. 4.2 GlaxoSmithKline
  8. 4.2.1 GlaxoSmithKline Company Information
  9. 4.2.2 GlaxoSmithKline Business Overview
  10. 4.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  12. 4.2.5 GlaxoSmithKline Recent Developments
  13. 4.3 Astellas Pharma
  14. 4.3.1 Astellas Pharma Company Information
  15. 4.3.2 Astellas Pharma Business Overview
  16. 4.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  18. 4.3.5 Astellas Pharma Recent Developments
  19. 4.4 Sanofi
  20. 4.4.1 Sanofi Company Information
  21. 4.4.2 Sanofi Business Overview
  22. 4.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  24. 4.4.5 Sanofi Recent Developments
  25. 4.5 Pfizer
  26. 4.5.1 Pfizer Company Information
  27. 4.5.2 Pfizer Business Overview
  28. 4.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  30. 4.5.5 Pfizer Recent Developments
  31. 4.6 Abbott
  32. 4.6.1 Abbott Company Information
  33. 4.6.2 Abbott Business Overview
  34. 4.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  36. 4.6.5 Abbott Recent Developments
  37. 4.7 Allergan
  38. 4.7.1 Allergan Company Information
  39. 4.7.2 Allergan Business Overview
  40. 4.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  42. 4.7.5 Allergan Recent Developments
  43. 4.8 TEVA
  44. 4.8.1 TEVA Company Information
  45. 4.8.2 TEVA Business Overview
  46. 4.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  48. 4.8.5 TEVA Recent Developments
  49. 4.9 Mylan
  50. 4.9.1 Mylan Company Information
  51. 4.9.2 Mylan Business Overview
  52. 4.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  54. 4.9.5 Mylan Recent Developments
  55. 4.10 Novartis
  56. 4.10.1 Novartis Company Information
  57. 4.10.2 Novartis Business Overview
  58. 4.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  60. 4.10.5 Novartis Recent Developments
  61. 4.11 Merck
  62. 4.11.1 Merck Company Information
  63. 4.11.2 Merck Business Overview
  64. 4.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  66. 4.11.5 Merck Recent Developments
5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Scenario by Region
  1. 5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2027-2032
  5. 5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032) & (M Units)
  3. 6.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032) & (M Units)
  3. 7.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
  2. 8.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
  5. 8.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
  8. 8.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
9 Global Benign Prostatic Hyperplasia (BPH) Drugs Analyzing Market Dynamics
  1. 9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
  2. 9.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
  3. 9.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
  4. 9.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst